ETONETONHealthcare · Drug Manufacturers - Specialty & Generic

ETON Stock Forecast: Eton Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$62
−2.56% on the day

The 4 Wall Street analysts covering Eton Pharmaceuticals, Inc. hold a median 12-month price target of $81 — +29.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 17 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.8B
Ticker Nerd rank
99/ 100
Median analyst target
$81
Analysts covering
4
Revenue$37.6M+98.6% y/y
Operating income$12.8M
Net income$11.6M
Free cash flow$7.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.3%
1M
+23.3%
YTD
+266.8%
1Y
+260.6%
From 52W high
−9.3%
From 52W low
+332.2%
$14
$68
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ETON stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Eton Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
99/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Revisions
99
Quality
96
Growth
94
Value
94
Volatility
81
Issuance
71
Size
35
Accruals
22

Momentum (100): The shares have been drifting up relative to others.

Accruals (22): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ETON stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ETON, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80Jan 26Apr 26Jul 26Oct 26ETONHigh $82Median $81Low $80

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $80Median $81High $82

The green dot is the last close — the median target sits +29.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
10 Nov 2026B. Riley SecuritiesMaintainsBuy$70 → $81
6 Nov 2026Canaccord GenuityMaintainsBuy$68 → $80
6 Nov 2026HC Wainwright & Co.MaintainsBuy$70 → $80
14 Oct 2026HC Wainwright & Co.ReiteratesBuy$70
14 Oct 2026HC Wainwright & Co.ReiteratesBuy—
14 Aug 2026B. Riley SecuritiesReiteratesBuy$40 → $70
14 Aug 2026B. Riley SecuritiesReiteratesBuy—
14 Aug 2026Canaccord GenuityMaintainsBuy—
14 Aug 2026Canaccord GenuityMaintainsBuy$60 → $68
14 Aug 2026HC Wainwright & Co.MaintainsBuy$65 → $70
14 Aug 2026HC Wainwright & Co.MaintainsBuy—
11 Aug 2026HC Wainwright & Co.MaintainsBuy$57 → $65
11 Aug 2026HC Wainwright & Co.MaintainsBuy—
28 July 2026Craig-HallumMaintainsBuy—
28 July 2026Craig-HallumMaintainsBuy$40 → $62
17 July 2026Canaccord GenuityInitiatesBuy$60
17 July 2026Canaccord GenuityInitiatesBuy—
15 May 2026HC Wainwright & Co.MaintainsBuy$52 → $57
15 May 2026HC Wainwright & Co.MaintainsBuy—
20 Mar 2026B. Riley SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ETON appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ETON vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Eton Pharmaceuticals, Inc. returned +260.6% against +12.2% for the S&P 500, dividends included.

ETON vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400Jan 26Apr 26Jul 26Oct 26ETONS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ETON analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+69.0%
Analysts raising
1
Analysts cutting
0
Fundamentals

Eton Pharmaceuticals, Inc. (ETON) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
41.5×

Cheaper than 17% of US stocks

Price / sales
13.1×

Cheaper than 11% of US stocks

Price / book
21.2×

Cheaper than 4% of US stocks

EV / EBITDA
36.9×

Cheaper than 6% of US stocks

Growth & margins
Revenue growth (YoY)
157.9%

Higher than 95% of US stocks

Earnings growth (YoY)
98.6%

Higher than 84% of US stocks

Gross margin
67.6%

Higher than 81% of US stocks

Operating margin
31.3%

Higher than 89% of US stocks

Net margin
35.3%

Higher than 92% of US stocks

Returns & dividend
Return on equity
90.6%

Higher than 96% of US stocks

Return on assets
21.1%

Higher than 99% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Eton Pharmaceuticals, Inc. (ETON) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Eton Pharmaceuticals, Inc. has a market value of $1.8B and an enterprise value of $1.8B.

  • Revenue in the twelve months to 30 June 2026: $105.6M. The latest quarter grew 157.9% year on year.

  • Net income over the same four quarters: $12.7M, a 12.0% net margin.

  • Diluted earnings per share, trailing twelve months: $0.38.

  • Free cash flow in the twelve months to 30 June 2026: −$268K.

  • Shares outstanding: 28.3M.

  • Trailing P/E: 41.5×; forward P/E: 19.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Eton Pharmaceuticals, Inc. employs 44 people — $2.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

ETON vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ETONEton Pharmaceuticals, Inc.$1.8B99
BCRXBioCryst Pharmaceuticals, Inc.$1.9B82
TRLVTrulieve Cannabis Corp.$1.9B71
ANIPANI Pharmaceuticals, Inc.$1.6B98
ALVOAlvotech$1.6B32
PRGOPerrigo Co. Plc$2.2B90
PCRXPacira Biosciences, Inc.$1.5B100

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Eton Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ETON news & analysis

Eton Pharmaceuticals: The Commercial Model Is Finally Scaling

Seeking Alpha · 16 Nov 2026positive

Seeking Alpha gives Eton Pharmaceuticals a Buy rating, citing 158% third-quarter revenue growth to $57.9 million, a 49% adjusted EBITDA margin, and increased 2026 revenue guidance of more than $175 million. The article identifies LIBERVANT and ASN-001 as growth drivers, with potential launches in 2027 and 2028, respectively.

Why it matters — The reported results, higher guidance, and planned launches highlight the commercial growth and pipeline milestones that ETON watchers may follow.

Eton Q3 Earnings Call Highlights Growth and Pipeline Expansion

Zacks Investment Research · 6 Nov 2026positive

Eton reported that third-quarter sales surged 158%, driven by HEMANGEOL growth, alongside improving profitability and progress in its rare disease pipeline. The company raised its 2026 revenue outlook.

Why it matters — The update highlights sales growth, profitability trends, and pipeline progress relevant to ETON watchers.

Eton Pharmaceuticals Q3 Earnings Call Highlights

MarketBeat · 6 Nov 2026positive

Eton Pharmaceuticals reported third-quarter revenue of $57.9 million, up 158% year over year, and raised its full-year outlook. The company cited a full quarter of HEMANGEOL sales and growth across its product portfolio.

Why it matters — The reported revenue growth and higher full-year outlook provide updates on Eton’s recent performance and expectations.

Eton Pharmaceuticals, Inc. (ETON) Q3 Earnings and Revenues Surpass Estimates

Zacks Investment Research · 6 Nov 2026positive

Eton Pharmaceuticals reported quarterly earnings of $1.06 per share, above the Zacks Consensus Estimate of $0.34. This compares with a loss of $0.07 per share a year earlier.

Why it matters — The results show ETON exceeded the cited earnings estimate and improved from a per-share loss in the year-ago quarter.

FAQ

Frequently asked questions about ETON stock

What is the ETON stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Eton Pharmaceuticals, Inc. have a median 12-month price target of $81, with estimates ranging from $80 to $82. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ETON stock a buy right now?

Of the 4 analysts covering Eton Pharmaceuticals, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Eton Pharmaceuticals, Inc. 99 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ETON?

As at 17 Nov 2026, Eton Pharmaceuticals, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will ETON stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +29.8% from the last close, and Ticker Nerd's factor model ranks Eton Pharmaceuticals, Inc. 99 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ETON stock forecast for 2030?

No analyst covering Eton Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ETON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $80 to $82 over the next 12 months.

How has ETON stock performed over the past year?

Eton Pharmaceuticals, Inc. returned +260.6% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Eton Pharmaceuticals, Inc. do?

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare and underserved diseases.

What is the latest news on ETON?

The most recent item we track (Seeking Alpha, 16 Nov 2026): "Eton Pharmaceuticals: The Commercial Model Is Finally Scaling". Seeking Alpha gives Eton Pharmaceuticals a Buy rating, citing 158% third-quarter revenue growth to $57.9 million, a 49% adjusted EBITDA margin, and increased 2026 revenue guidance of more than $175 million. The article identifies LIBERVANT and ASN-001 as growth drivers, with potential launches in 2027 and 2028, respectively.

Company

About Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare and underserved diseases. Eton Pharmaceuticals, Inc. offers a commercial portfolio that includes therapies for adrenal insufficiency, severe primary IGF-1 deficiency, Wilson disease, phenylketonuria, homocystinuria, tyrosinemia type 1, and central diabetes insipidus, along with prescription products such as oral suspensions, injectable formulations, and oral solutions. The company also works across pediatric and adult care settings, supporting medications used in endocrine, metabolic, and other niche therapeutic areas. Based in Deer Park, Illinois, Eton Pharmaceuticals, Inc. plays a focused role in the rare-disease market by bringing specialized medicines to patients and healthcare providers through a mix of in-licensed products, commercial launches, and targeted product development.

CEO Mr. Sean E. Brynjelsen · 44 employees · United States · https://www.etonpharma.com